Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04604860
Other study ID # STUDY19020063
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 23, 2020
Est. completion date February 24, 2022

Study information

Verified date June 2022
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Transplant-eligible patients with cirrhosis and ESLD, age 40-70, MELD >/= 10 referred to transplant physical therapy will be invited to participate. The investigators will exclude those who lack a smartphone or the understanding of its functionality, lack home wireless internet, or have recurrent/persistent overt hepatic encephalopathy. Following signing of informed consent, each participant will be given a Fitbit Charge 3 and have EL-FIT and Fitbit apps downloaded to their smartphone. After a brief session with a member of the research team explaining the basic components and functionality of EL-FIT and Fitbit, patients will be provided with general physical activity recommendations (as per our current standard of care) and asked to explore all features of EL-FIT and Fitbit apps, up until their 12-week follow-up visit. Phone calls to incentivize physical activity and exercise will be performed by members of the research team.


Description:

The study consists of two visits, baseline and 12-week follow-up, with at least one follow-up phone call on a weekly basis. Visit one is expected to last for 30 minutes and visit 2 for 60 minutes, whereas each phone call should take no more than 15 minutes. Twice during the study period, the investigators will draw serum and plasma samples for future translational research. Daily, the physical trainer will review collected data on EL-FIT research database and Fitabase. Each participant will have an exit interview by the end of week 12 with the trainer and a member of the research team to talk about their impressions of using EL-FIT and Fitbit, through a structured questionnaire assessing about how user friendly it was to use the EL-FIT app. Finally, trainers will be asked to compare the type of prescription that they provided to patients as part of the standard of care (based on liver frailty index or 6-minute walk test), to compare it with the allocation provided by EL-FIT stratification algorithm. To learn about how to improve EL-FIT the investigators will ask patients and their caregivers open-ended questions as part of their exit interview. This will allow us to identify barriers precluding them from keeping up with physical trainer recommendations, and what would they like to include to enhance motivation as part of a physical activity program. A member of the research team will act as a facilitator during this session.


Recruitment information / eligibility

Status Completed
Enrollment 59
Est. completion date February 24, 2022
Est. primary completion date February 24, 2022
Accepts healthy volunteers No
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - cirrhosis and ESLD - transplant eligible - MELD >/=10 - referred to transplant physical therapist Exclusion Criteria: - those who lack a smartphone or the understanding of its functionality - lack home wireless internet - have recurrent/persistent overt hepatic encephalopathy

Study Design


Intervention

Behavioral:
Fitness intervention
Patients will follow exercise plans designed to promote physical activity (exercise and behavioral coaching).

Locations

Country Name City State
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
University of Pittsburgh American Association for the Study of Liver Diseases (AASLD), Pittsburgh Liver Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in liver frailty index (LFI) score Change in liver frailty index from baseline to the end of the study 12 weeks
Primary Change in six minute walk test (6MWT) Change in six minute walk test from baseline to the end of the study 12 weeks
Secondary Change in daily average steps Comparison of average daily steps from baseline until the end of study 12 weeks
Secondary Usability of EL-FIT app How patient interacts with each of the features of EL-FIT app based on responses to questionairre 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05793983 - S100A8/A9 and Innate Immunity in Liver Disease
Recruiting NCT05928624 - A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients N/A
Active, not recruiting NCT01438970 - Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function Phase 2
Recruiting NCT05998330 - LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease N/A
Completed NCT04581369 - Cirrhosis Medical Home N/A
Withdrawn NCT04244877 - Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility Phase 3
Recruiting NCT04588077 - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis Phase 4
Recruiting NCT05538962 - Longitudinal Monitoring of Inflammation in Cirrhosis N/A
Completed NCT04082780 - Rifamycin in Minimal Hepatic Encephalopathy Phase 2
Completed NCT03850977 - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Active, not recruiting NCT03736265 - Carvedilol for Prevention of Esophageal Varices Progression N/A
Recruiting NCT04530760 - Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation
Recruiting NCT05093218 - Effect of Branch Chain Amino Acid Therapy on Sarcopenia in Children With Chronic Liver Disease. N/A
Recruiting NCT03437876 - Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis N/A
Recruiting NCT05604274 - Longitudinal Monitoring of Stool Characteristics
Recruiting NCT04867954 - Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
Completed NCT04643795 - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects Phase 1
Active, not recruiting NCT02344680 - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed NCT04121520 - Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
Not yet recruiting NCT04591522 - Fecal Microbiota Transplantation in Cirrhosis N/A